GLAXF - GlaxoSmithKline plc

Other OTC - Other OTC Delayed price. Currency in USD
21.12
0.00 (0.00%)
At close: 2:43PM EDT
Stock chart is not supported by your current browser
Previous close21.12
Open21.27
Bid0.00 x 0
Ask0.00 x 0
Day's range21.12 - 21.12
52-week range18.14 - 21.71
Volume53
Avg. volume6,098
Market cap105.215B
Beta (3Y monthly)0.53
PE ratio (TTM)42.58
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield0.93 (4.44%)
Ex-dividend date2019-08-08
1y target estN/A
Trade prices are not sourced from all markets
All
News
Press releases
  • Business Wire

    Nucala is the first biologic approved in the US for six to 11-year-old children with severe eosinophilic asthma

    GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for use in children as young as six years old who are living with severe eosinophilic asthma. Nucala is the only targeted biologic to be approved for the condition in the six to 11-year age group in the US. Dr Hal Barron, Chief Scientific Officer and President, R&D, GSK, said: “Children with severe eosinophilic asthma currently have limited treatment choices available to them.

  • Business Wire

    Nucala (mepolizumab) Gains FDA Approval for Two New Self-Administration Options

    GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an autoinjector and a pre-filled safety syringe, for patients or caregivers to administer once every four weeks, after a healthcare professional decides it is appropriate. This is the first anti-IL5 biologic to be licensed in the US for at-home administration, and the first respiratory biologic to be approved for administration via an autoinjector. This approval will give healthcare professionals and people living with severe eosinophilic asthma (SEA) or the rare disease eosinophilic granulomatosis with polyangiitis (EGPA) the option for Nucala to be administered outside of a clinical setting by a patient or caregiver after their healthcare professional agrees this approach is appropriate.

  • Business Wire

    Phase III CAPTAIN Study of Trelegy Ellipta in Patients with Asthma Meets Primary Endpoint

    LONDON--(BUSINESSWIRE)-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced headline results from the pivotal phase III CAPTAIN study of once-daily single inhaler triple ...

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more